Articles with keyword targeted therapy
Targeted therapy: twenty years of success and failures (S.A. Tyulyandin)
targeted therapy, oncology, cancer, melanoma, tumor evolution.
What has changed in clinical oncology practice In 2019? (M.Y. Fedyanin)
cancer, chemotherapy, immunotherapy, targeted therapy.
Colorect al molecular subtypes – progress or deadlock ? (M.Yu. Fedyanin, E.O. Ignatova, А.А. Tryakin)
colorectal cancer, molecular subtypes, immunotherapy, targeted therapy.
20 YEARS OF TARGETING THERAPY OF SOLID TUMORS. SUCCESSES AND FAILURES (A.A. Tryakin, M.Yu. Fedyanin, I.A. Pokataev)
targeted therapy, precision medicine, tyrosine kinase inhibitor, biomarker, oncology; review.
immunotherapy, targeted therapy, checkpoint inhibitors, urothelial cancer, renal cell cancer.
MATHEMATICAL MODELING AND OPTIMIZATION OF TARGETED TUMOR THERAPY (A.A. Bogdanov)
cancer, targeted therapy, mathematical modeling, forecasting, new regimens of therapy.
2015 main events in drug therapy (F.V. Moiseenko)
immunotherapy, program cell death protein inhibitors, targeted therapy, cancer drug therapy
non-small cell lung cancer, epidermal growth factor receptor, targeted therapy, resistance.
EVOLUTION OF DRUG THERAPY FOR LUNG CANCER WITH EGFR INHIBITORS: NEW ASPECTS (M.L. Stepanova, L.V. Khalicova, A.S. Zhabina, F.V. Moiseenko)
non-small cell lung cancer, epidermal growth factor receptor, targeted therapy, osimertinib.
2016: new directions in radiation therapy (N.V. Dengina, T.V. Mitin, A.O. Likhacheva)
radiotherapy, breast cancer, prostate cancer, targeted therapy, abscopal effect, hepatocellular carcinoma, intrahepatic cholangiocarcinoma
Clinical experience of afatinib application In non-cell lung cancer of lung. Ii line of therapy (L.M. Kogoniya, E.V. Markarova, G.A. Stashuk, V.E. Shikina)
lung cancer, adenocarcinoma, non-small cell lung cancer, EGFR mutation, chemotherapy, targeted therapy, efficacy, elderly, side effects